Posts for Ticker ‘XCR’

More ‘Going Concern’ Notes Hitting Companies (AWBC, AHR, BWTR, CHCI, DCGN, GST, MLP, OXGN, TMI, XCR)

burning-money-picThis might be a record year for auditor “going concern” notes being included in annual report filings with the SEC. If it isn’t a record, it sure feels like it.  This note in an annual report is either from the company or its auditor(s) that there is a risk that the company will not be able to operate without bringing in new capital or be operated in the same manner financially.
Read More »

Posted on: April 1, 2009 – 10:07 am in Accounting, Annual Report, SEC, , , , , , , , , ,

Cramer Speculates on Dialysis Drug (AMAG, XCR)

On tonight’s MAD MONEY on CNBC, Jim Cramer said he had a speculative biotech stock.  His pick in the sector is AMAG Pharmaceuticals, Inc. (AMAG) because of its soon to be approved  ferumoxytol, a newer and better intravenous iron treatment for kidney disease patients on dialysis.    Cramer thinks there are many reasons to like this one:

  • ferumoxytol should be approved later in the year;
  • he thinks a secondary has put pressure on it, although that gives it more cash to stabilize the stock;
  • has its own strong sales force;
  • was given an untimely and unwarranted analyst downgrade;
  • will perform better than existing drugs on the market;
  • a competing biotech drug received negative FDA comments on safety, yet that isn’t AMAG’s issue; and he thinks this can expand the market from $400 million annually to much higher.

We recently covered a speculative portable dialysis device maker (in prototype and development stage) on our "10 Stocks Under $10" called Xcorporeal, Inc. (AMEX: XCR) which has risen in the last two weeks since being included.  We have also reviewed some of the lower-tier dialysis names for this as well.

We would note that this AMAG traded at $56.00 after an upgrade just in early February and shares closed under $40.00 Friday.

Jon C. Ogg
March 28, 2008

Jon Ogg produces the Special Situation Investing Newsletter and he can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: March 28, 2008 – 5:51 pm in Biotech, Cramer, ,

Microcap Featured in Dialysis Investing (XCR, NXTM, DVA, FMS, DCAI)

Xcorporeal, Inc. (AMEX: XCR) is a potential undiscovered gem in microcap and low-priced stock investing, and it is in the arena of kidney dialysis.  This week’s "INSIDE WALL STREET" segment in Business Week featured this stock, and this may be their most unusual pick in months with perhaps the greatest upside potential if it can live up to the hopes and plans.

This one has been under review for our "10 Stocks Under $10" weekly letter, although we have not yet added it to the list because of its performance and lack of history.  Xcorporeal first came to us after it’s Wearable Artificial Kidney (WAK) prototype device was featured in the December 15, 2007 journal issue of The Lancet, an influential medical journal.

It is entering a space dominated by public companies such as DaVita Inc. (NYSE: DVA), Dialysis Corp. of America (NASDAQ: DCAI), Fresenius Medical Care AG & Co. KGaA (NYSE: FMS), and Nxstage Medical, Inc. (NASDAQ: NXTM). Of the public dialysis companies, this is also the most risky stock of the ones we have reviewed in the dialysis companies.

Read More »

Posted on: March 14, 2008 – 7:21 am in Medical, , , , ,